Drug Interaction and Safety Considerations for Aluminum‑Magnesium Antacid Combinations

Drug‑Drug Interactions

Azithromycin: To prevent a clinically significant reduction in azithromycin bioavailability, the antacid should be administered at least 1 hour before or 2 hours after azithromycin dosing. This recommendation is based on CDC MMWR guidance. 1

Aluminum hydroxide as a phosphate binder: In patients with CKD, aluminum hydroxide may be used as a low‑cost phosphate binder but should be limited to 1–2 days of therapy to avoid the risk of aluminum toxicity. (Evidence from oncology and nephrology literature.) [2][3]
Long‑term aluminum exposure: Prolonged use of aluminum‑containing antacids in CKD patients is associated with bone disease and neurotoxicity. (Nephrology study.) 3
Magnesium‑containing products: In CKD, magnesium‑based antacids require caution because of the potential for magnesium accumulation in the setting of impaired renal clearance. (Kidney disease research.) 4

Rapid onset but short duration: Aluminum‑magnesium antacids act quickly to neutralize gastric acid, yet their therapeutic effect lasts shorter than that of H₂‑receptor antagonists or proton‑pump inhibitors. (Pediatrics guideline.) 5
GERD symptom relief in children: Historical data suggest that antacids provide limited symptom relief for pediatric gastro‑esophageal reflux disease and are generally considered relatively benign but not a first‑line therapy. (Pediatrics guideline.) 5